Alan Zhou's practice is focused in the areas of mergers & acquisitions, private equity/venture capital, regulatory compliance, and general corporate. Mr. Zhou has a particularly strong background in pharmaceutical and healthcare industrial sectors.
Mr. Zhou has represented many multinational corporations, reputable Chinese state owned and private corporations, and private equity/venture capital funds. He has routinely represented such multinational corporations as Sanofi, Schlumberger, Siemens, Boehringer Ingelheim, Novartis, Aon, Bureau Veritas, Catalent, Terumo, Tosoh, Barclays, Societe Generale Bank, Samsung and SK Telecom. Mr. Zhou has not only worked for reputable Chinese private companies such as Focus Media, VIPShop, Acorn International, Hisoar Pharmaceutical, Tianyuan Biopharm, and GeneScience Pharma, he has also advised PRC state owned companies such as Shanghai Dasheng, Shanghai Industrial and Shanghai Airport Authority. In the area of PE/VC, Mr. Zhou has acted for CBRE Investors, Colony Capital, Navis Capital, Lightspeed Ventures, Qiming Ventures, DT Capital, NEA, New Alliance Capital, Warden International, WINS and other international and local PE/VC funds.
Mr. Zhou has been seconded as general counsel for China operations of Boehringer Ingelheim, a leading multinational pharmaceutical company, for more than nine years, and is responsible for various legal matters including general corporate, acquisitions and joint venture formation, compliance and regulatory, intellectual property and corporate restructuring.
China Europe International Business School Executive MBA
College of Law, Shanghai International Studies University L.L.B.
Mr. Zhou has been ranked as a Tier 1 Lawyer in the Healthcare field, and as a leading lawyer in M&A and Capital Market by Chambers & Partners in 2012, 2013 and 2014.
He has also been identified as a leading legal expert in Corporate/ M&A in China by Asialaw Leading Lawyers 2014, and as a leading practitioner in M&A by the Guide to Leading Practitioners (Legal Media Group) 2013.
Mr. Zhou is the standing director of CEIBS Alumni Healthcare Association and is also an investment partner of HGI FINAVES China Fund.
